Skip to content

Comparison of Ticagrelor versus Clopidogrel in patients with acute myocardial infarction

Comparison of ticagrelor with clopidogrel on myocardial blood flow and prognosis of patients with acute myocardial infarction undergoing primary percutaneous coronary intervention

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210718051935N1
Enrollment
140
Registered
2021-08-16
Start date
2021-08-11
Completion date
Unknown
Last updated
2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute myocardial infarction. ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention 1: Intervention group: Ticagllor group: for patients will be prescribed 180 mg of ticaglor loading dose and then 75 mg ticaglor twice a day as maintenance dose for 3 months. Intervention

Sponsors

Qazvin University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age > 18 years Presented with ST-Elevation Myocardial Infarction (STEMI) Suitable infarcted related artery for angioplasty Patient satisfaction

Exclusion criteria

Exclusion criteria: More than single vessel involvement in angiography Unprotected left main lesion in angiography Stent thrombosis Presentation with cardiogenic shock History of CVA History of MI Contraindication of adenosine High degree AV block TIMI flow < 3 at the end of the angioplasty Patient dissatisfaction

Design outcomes

Primary

MeasureTime frame
Thrombosis. Timepoint: Before intervention and 3 months after intervention. Method of measurement: Clinical signs and laboratory tests.

Secondary

MeasureTime frame
Duration of hospitalization. Timepoint: 3 months after the intervention. Method of measurement: Use of patient records.;Death. Timepoint: 3 months after the intervention. Method of measurement: Use of patient records.;Bleeding Time. Timepoint: 3 months after the intervention. Method of measurement: Use of patient records.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemah Rajabi

Qazvin University of Medical Sciences

F_rajabi_r@yahoo.com+98 28 3333 2930

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026